This application of the Comprehensive Cancer Center of Wake Forest University (CCCWFU) requests renewal of its Cancer Center Support Grant for Years 33 through 37. During the current grant period, peer-reviewed annual direct cancer funding increased from $10.8 to $25.4 million, NCI funding increased from $5.1 to $12 million, and annual direct funding per member increased from $106,000 to $233,000. Interprogrammatic publications increased from 9.1% to 11.8%, intraprogrammatic publications increased from 16.7% to 28.6%, and interdepartmental publications increased from 17.4% to 28.7%. Formal collaboration (co-investigators, consultants, or collaborators) with other Cancer Center members is present on 68.5% of peer-reviewed research grants listed in summary II. In the current grant cycle we have made few structural changes, and instead focused on the execution of our scientific vision. Support is requested for four Programs: Cell Growth and Survival, DNA Damage and Cellular Defense, Clinical Research and Cancer Control as well as seven shared resources: Biomolecular Resource Laboratory, Cell Culture and Viral Vector, Microarray, Cellular Imaging, Tumor Tissue, Biostatistics, and Clinical Research Management. During this funding period, the CCCWFU opened a new 225,000 sq.ft. outpatient cancer center, and continued its longstanding focus and unique contributions to the cancer problems in our 7 state catchment area. The blueprint for our next five years is embodied in this application, which provides the Center's vision of how it can reduce the burden of cancer in our region and in the nation.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Center Core Grants (P30)
Project #
3P30CA012197-36S1
Application #
8322899
Study Section
Subcommittee G - Education (NCI)
Program Officer
Ptak, Krzysztof
Project Start
1997-02-01
Project End
2012-01-31
Budget Start
2011-02-01
Budget End
2012-01-31
Support Year
36
Fiscal Year
2011
Total Cost
$74,984
Indirect Cost
Name
Wake Forest University Health Sciences
Department
Internal Medicine/Medicine
Type
Schools of Medicine
DUNS #
937727907
City
Winston-Salem
State
NC
Country
United States
Zip Code
27157
Paek, M-S; Nightingale, C L; Tooze, J A et al. (2018) Contextual and stress process factors associated with head and neck cancer caregivers' physical and psychological well-being. Eur J Cancer Care (Engl) 27:e12833
Dutta, Samrat; Rivetti, Claudio; Gassman, Natalie R et al. (2018) Analysis of single, cisplatin-induced DNA bends by atomic force microscopy and simulations. J Mol Recognit 31:e2731
Pardee, Timothy S; Anderson, Rebecca G; Pladna, Kristin M et al. (2018) A Phase I Study of CPI-613 in Combination with High-Dose Cytarabine and Mitoxantrone for Relapsed or Refractory Acute Myeloid Leukemia. Clin Cancer Res 24:2060-2073
Atkins, Hannah M; Appt, Susan E; Taylor, Robert N et al. (2018) Systemic Iron Deficiency in a Nonhuman Primate Model of Endometriosis. Comp Med 68:298-307
Godwin, Ryan C; Gmeiner, William H; Salsbury Jr, Freddie R (2018) All-atom molecular dynamics comparison of disease-associated zinc fingers. J Biomol Struct Dyn 36:2581-2594
Yang, M; Forbes, M E; Bitting, R L et al. (2018) Incorporating blood-based liquid biopsy information into cancer staging: time for a TNMB system? Ann Oncol 29:311-323
Votanopoulos, Konstantinos Ioannis; Bartlett, David; Moran, Brendan et al. (2018) PCI is Not Predictive of Survival After Complete CRS/HIPEC in Peritoneal Dissemination from High-Grade Appendiceal Primaries. Ann Surg Oncol 25:674-678
Lamar, Zanetta S; Dothard, Andrew; Kennedy, LeAnne et al. (2018) Hyperglycemia during first-line R-CHOP or dose adjusted R-EPOCH chemotherapy for non-Hodgkin lymphoma is prevalent and associated with chemotherapy alteration - a retrospective study. Leuk Lymphoma 59:1871-1877
Melvin, Ryan L; Xiao, Jiajie; Berenhaut, Kenneth S et al. (2018) Using correlated motions to determine sufficient sampling times for molecular dynamics. Phys Rev E 98:023307
Bhatt, Nikunj B; Pandya, Darpan N; Dezarn, William A et al. (2018) Practical Guidelines for Cerenkov Luminescence Imaging with Clinically Relevant Isotopes. Methods Mol Biol 1790:197-208

Showing the most recent 10 out of 548 publications